Chief Financial Officer · Spyre Therapeutics, Inc. · Spyre Therapeutics, Inc. — Stock Option (Right to Buy)
Side
M
Value
—
Shares
12.5K
Price
—
Executed
May 1, 2026
Disclosed
May 1, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
May 1 executedMay 1, 2026 disclosed
SYRE · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Option exercise — administrative, little informational value
Relative size+1 / 25
No reported dollar value · 3.4% of prior position
Filing timing0 / 15
Disclosed 0 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Spyre Therapeutics, Inc. — Stock Option (Right to Buy)
Ticker
SYRE
Shares
12.5K
Price per share
$0
Execution date (reported)
May 1, 2026
Owned after transaction
382.4K shares
Rule 10b5-1 plan
Yes, as checked by the filer
Days from execution to publication
0
What this establishes
Burrows Scott L filed this Form 4 reporting a option exercise of SYRE on May 1, 2026. It became public on May 1, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Financial Officer
Burrows Scott Lcik:0001853327
Issuer
Spyre Therapeutics, Inc.cik:0001636282
Revision history · 0
No field has changed since this record was first ingested.
